P. Danchaivijtr

发表

KEYNOTE‐033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD‐L1‐positive, advanced NSCLC

Changli Wang, I. Vynnychenko, V. Sriuranpong, 2023, International journal of cancer.

1262P Randomized, open-label phase III study of pembrolizumab (pembro) vs docetaxel (doce) in patients (pts) with previously treated NSCLC with PD-L1 tumour proportion score (TPS) ≥1%: KEYNOTE-033

C. Zhou, I. Vynnychenko, V. Sriuranpong, 2020 .